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Introduction: Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is
limited by the development of drug resistance. Here, we investigated the role of estrogen G-protein coupled
receptor 30 (GPR30) on Tamoxifen resistance in breast cancer.
Methods: Primary tumors (PTs) of breast cancer and corresponding metastases (MTs) were used to evaluate the
expression of GPR30 and epidermal growth factor receptor (EGFR) immunohistochemically. Tamoxifen-resistant
(TAM-R) subclones derived from parent MCF-7 cells were used to investigate the role of GPR30 in the development
of tamoxifen resistance, using MTT assay, western blot, RT-PCR, immunofluorescence, ELISA and flow cytometry.
TAM-R xenografts were established to assess anti-tumor effects of combination therapy with GPR30 antagonist G15
plus 4-hydroxytamoxifen (Tam), using tumor volume measurement and Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL).
Results: In 53 human breast cancer specimens, GPR30 expression in MTs increased compared to matched PTs; in
MTs, the expression patterns of GPR30 and EGFR were closely related. Compared to parent MCF-7 cells, TAM-R cells
had greater growth responses to 17β-estradiol (E2), GPR30 agonist G1 and Tam, and significantly higher activation
of Mitogen-activated protein (MAP) kinases; but this increased activity was abolished by G15 or AG1478. In TAM-R
cells, GPR30 cell-surface translocation facilitated crosstalk with EGFR, and reduced cAMP generation, attenuating
inhibition of EGFR signaling. Combination therapy both promoted apoptosis in TAM-R cells and decreased
drug-resistant tumor progression.
Conclusions: Long-term endocrine treatment facilitates the translocation of GPR30 to cell surfaces, which interferes
with the EGFR signaling pathway; GPR30 also attenuates the inhibition of MAP kinases. These factors contribute to
tamoxifen resistance development in breast cancer. Combination therapy with GPR30 inhibitors and tamoxifen may
provide a new therapeutic option for drug-resistant breast cancer.Introduction
Tamoxifen is commonly used as an anti-estrogen treat-
ment for patients with hormone-dependent breast cancer
[1,2]. Although most patients benefit from this therapy,
approximately 50% of responsive tumors eventually re-
lapse due to development of tamoxifen resistance [3,4].
Acquired tamoxifen resistance is a crucial therapeutic
problem for which several molecular mechanisms have
been proposed to be responsible [5].
Tamoxifen resistance mechanisms are complex. In-
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reproduction in any medium, provided the orreceptor (EGFR) signaling pathway readily promotes
anti-hormonal treatment failure in breast cancer [6-8];
EGFR over-expression reportedly decreases sensitivity to
endocrine therapy in breast cancer patients [9]. EGFR
downstream elements, which directly stimulate prolifera-
tive and survival signaling, are extraordinarily active in
tamoxifen-resistant (TAM-R) cells [10-12]. These pivotal
intermediates can also phosphorylate the AF-1 domain
on estrogen receptor (ER) protein, transforming the
tamoxifen–ER complex into a positive nuclear transcrip-
tion factor [13]. However, initial mechanisms of in-
creased EGFR activation are still undefined.
The G-protein coupled receptor 30 (GPR30), a seven-
transmembrane domain protein, was recently identified
as a novel estrogen receptor structurally distinguished. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulator tamoxifen, its metabolites, 4-hydroxytamoxifen
(Tam), estrogen or the pure anti-estrogen fulvestrant, act-
ing as a GPR30 agonist, could induce rapid non-genomic
effects in breast cancer cells [15]. Reportedly approxi-
mately 50% of breast cancer patients express GPR30,
which is consistent with development of tamoxifen resist-
ance [16,17]. In breast cancer cells, estrogen activated-
GPR30 cleaves into Gα and Gβγ. The Gβγ subunit, which
modulates nongenomic signaling events, increases SRC-
like tyrosine kinase activation, leading to phosphorylation
of adaptor protein SHC by activating metalloproteases;
this results in extracellular release of heparin-bound epi-
dermal growth factor (HB-EGF) [18-20]. Release of HB-
EGF can stimulate the EGFR signaling pathway, leading to
induction of Erk1/2 phosphorylation [20]. Interestingly,
the Gα subunit attenuates Erk1/2 activity via inhibitory ac-
tivation of protein kinase A on RAF1 through cAMP gen-
eration [18,21]. Inhibition and stimulation of Erk1/2 are
mediated by estrogen in breast cancer cells [18,20,21].
Here, we hypothesized that tamoxifen activates crosstalk
between the GPR30 and the EGFR signaling pathway,
while suppressing ER activation in GPR30/ER + breast
cancer patients. As GPR30/EGFR crosstalk intensifies
under endocrine therapy, breast cancer develops tamoxi-
fen resistance due to growth stimulation induced by EGFR
signaling.
We found that in 73.58% (39/53) of metastasis (MT)
specimens, GPR30 expression, which is associated with
EGFR expression, increased compared to their correspon-
ding primary tumors (PTs). In MCF-7 cells, Tam treatment
causes GPR30 to translocate to the cell surface, where it
interacts with the EGFR signaling pathway. Moreover,
GPR30 also reduces cAMP generation which, in turn,
attenuates cAMP’s inhibition of EGFR downstream
elements. Combination therapy with GPR30 inhibitor and
Tam could promote initiation of apoptosis in TAM-R cells,
while discouraging drug-resistant xenograft progression.
Together, our results suggest that GPR30 interference with
the EGFR signaling pathway is an initial factor in develop-
ment of tamoxifen resistance in breast cancer.
Methods
Materials
All chemicals and antibiotics for cell culture were
purchased from Beyotime (Haimen, China). Tam, 17β-
estradiol (E2), dimethyl sulfoxide (DMSO) and 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) were obtained from Sigma-Aldrich (Steinheim,
Germany). GPR30 agonists G1 and antagonist G15 were
purchased from Tocris (Ellisville, USA). Rabbit anti-
GPR30 polyclonal antibody was purchased from Abcam
(Cambridge, UK). Affinity-purified rabbit antibody against
EGFR was obtained from Bio-world (Saint Louis Park,MN, USA). Fluorescein isothiocyanate 4′, 6-diamidino-
2-phenylindole (DAPI), diaminobenzidine (DAB) detec-
tion and secondary antibody conjugated with horseradish
peroxidase (HRP) were obtained from Zsbio (Beijing,
China). (D)MEM, GPR30 antisense oligonucleotides and
β-actin antisense oligonucleotides were purchase from
Invitrogen (New York, US).
Cell culture
Human MCF-7 breast carcinoma cells (MCF-7) were
purchased from Institute of Biochemistry and Cell Biology,
Chinese Academy of Sciences (IBCB, Shanghai, China) and
routinely grown in (D)MEM containing 5% fetal bovine
serum (FBS), 10 μg/ml insulin, 100 U/ml penicillin, and
100 μg/ml streptomycin. TAM-R sublines were isolated by
exposing high-density MCF-7 cells to 1 × 10-6 M Tam for
30 days [22]. Matched control cells were obtained by
culturing MCF-7 cells in medium containing 0.1% ethanol.
To maintain drug resistance, TAM-R cells were grown
continuously in (D)MEM supplemented with 5% FBS and
1 × 10-7 M Tam. All cell lines were cultured at 37°C in a
humidified 5% CO2 atmosphere. Before all experiments,
cells were switched to phenol red-free (D)MEM containing
0.5% charcoal-dextran–stripped FBS for two days, excepted
where noted.
The experiments performed in this study do not re-
quired Institute Ethics Board approval, because only
commercially available cell lines were used.
Specimens
The 77 archival paraffin-embedded breast cancer speci-
mens were obtained from the Clinical Diagnostic Path-
ology Center, Chongqing Medical University (Chongqing,
China). All patients, who underwent surgery at the 1st
Affiliated Hospital of Chongqing Medical University from
1999 to 2011 were diagnosed by the same center and were
only treated with tamoxifen after surgery. Exclusion
criteria included a previous history of adjuvant anti-
hormonal or cytostatic treatment, primary non-operable
tumor and incomplete follow-up data. Median age at the
time of primary diagnosis was 50.6 years (range: 28 to 91
years). The follow-up was performed at the first re-
currence of disease. The median follow-up time of
the study population was 61 months (range: 1 to 144
months). All patients involved in this study consented
to participate in the study and publication of its re-
sults. The experiments were approved by the Ethics
Committee of the First Affiliated Hospital of Chongqing
Medical University and were conducted in compliance
with the Helsinki Declaration.
Immunohistochemistry
Sections of paraffin-embedded breast cancer specimens
were mounted on SuperFrost Plus Glass Slides (Zsbio,
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Streptavidin-Peroxidase Kit (Zsbio, Beijing, China) ac-
cording to the manufacturer’s instructions. The slides
were incubated with commercial rabbit anti-GPR30
polyclonal antibody diluted 1:250, and affinity-purified
rabbit antibody against EGFR diluted 1:200, for 2 hours
at 37°C, then exposed to horseradish peroxidase-conju-
gated goat anti-rabbit IgG for 20 minutes at 37°C. Reac-
tions were visualized by DAB detection. Nuclei were
counterstained with Mayer’s modified hematoxylin.
Evaluation of GPR30 and EGFR staining results
A modified semi-quantitative scoring system was used
to evaluate the intensity of immunoactive areas. Scores
were applied as follows: staining extent was classified as:
0, negative staining in all cells; 1, <1% cells stained; 2,
1% to 10% of cells stained; 3, 11% to 40% cells stained; 4,
41% to 70% cells stained; 5, 71% to 100% cells stained.
Staining intensity was classified as: 0, negative; 1, weak;
2, moderate; 3, strong. Extent and intensity scores were
multiplied to give total immunohistochemical (IHC)
scores, ranging from 0 to 8. GPR30+ expression was de-
fined for specimens that scored ≥2.
For assessment of EGFR expression, scores were ap-
plied as follows: 0, no staining; 1, weak and incomplete
staining of more than 10% of cells; 2, moderate and
complete staining of more than 10% of cells; 3, strong
and complete staining of more than 10% of cells.
Growth assay
For these experiments, cells were seeded in 96-well
plates at a density of 1 × 104 cells per well. Two days
later, the cells were treated with different concentrations
of E2, G1 or Tam for five days with medium replace-
ment on day three. The final concentration of vehicle
(DMSO) was 0.1%. At the end of treatment, cells were
incubated with 20 μl of 5 mg/ml MTT for four hours at
37°C under a culture hood. After removing medium,
MTT solvent was added to each well for 15 minutes; a
digital spectrophotometer was used to measure 590 nm
optical density (OD) value, which was expressed as per-
cent (%) of control.
Immunofluorescent microscopy
For these experiments, cells were grown on sterile glass
coverslips in 6-well plates at a density of 1 × 105 cells per
well. After 24 hours, cells were washed with cold PBS,
fixed in paraformaldehyde for 20 minutes and perme-
abilized in 0.1% Triton for 15 minutes at room tempe-
rature. After background blocking with 5% goat serum
in PBS for 30 minutes, cells were incubated with anti-
GPR30 antibody overnight at 4°C. After incubation in
primary antibody, secondary antibody conjugated with
green fluorescent protein (GFP) was applied at roomtemperature for one hour. Excess antibody was removed
by washing in PBS. Coverslips were mounted in vecta-
shield with DAPI. For antibody specificity, cells incu-
bated with secondary antibody served as controls. Cells
were visualized using Nikon Phase Contrast Eclipse 80i.
The images were collected using NIS-Elements software.
RT-PCR
Total RNA was extracted from MCF-7 and TAM-R cells
using RNAiso reagent (TaKaRa, Dalian, China) following
the manufacturer’s instruction. cDNA was generated from
total RNA via a PrimeScript RT reagent Kit (TaKaRa). To
verify cDNA integrity and primer specificity, GPR30 and β-
actin were amplified by conventional PCR in an automatic
Thermal Cycler using GPR30 specific sense-primer, 5′-
TCACGGGCCACATTGTCAACCTC-3′, antisense primer,
5′-GCTGAACCTCACATCTGACTGCTC-3′ and β-actin
specific sense primer, 5′-TGACGTGGACATCCGCAA
AG-3′, antisense primer, 5′-CTGGAAGGTGGACAGC
GAGG-3′. The PCR amplified products were separated
by electrophoresis in 1.5% agarose gels to visualize the
products. Quantitative real-time PCR was conducted by
Bio-Rad Miniopticom Real time PCR system using
SYBR® Premix EX Taq™ II Kit (TaKaRa, Dalian, China).
All the samples were amplified by real-time PCR twice
and normalized to β-actin. Data were analyzed by com-
parison with a serial dilution series of cell cDNA.
Immunoblotting
For these experiments, cells were cultured in 60-mm tis-
sue culture plates at a density of 1 × 105 cells per plate.
Two days later, cells were treated as described in the fig-
ure legends for various times indicated in the results.
Ethanol-treated cells were used as controls. After that,
all the cells were washed with cold PBS and incubated
on ice for five minutes with 200 μl lysis buffer (20 nM
Tris (pH7.5), 150 nM NaCl, 1 mM β-glycerophosphate,
1 μg/ml leupeptin and aprotinin, 1 mM phenylmethane-
sulfonyl fluoride (PMSF)). Subcellular protein fractions
were extracted using a Cell Membrane Protein Extrac-
tion Kit from Beyotime following the manufacturer’s in-
structions. All the samples were stored at −80°C until
analysis.
Cellular proteins (50 μg) were boiled in SDS-PAGE
sample loading buffer and separated on 10% SDS-PAGE.
Proteins were electrotransferred onto polyvinylidene
difluoride (PVDF) membranes using a Trans-Blot SD
Semi-Dry Eletrophoretic Transfer Cell. The membranes
were blocked overnight in Tris-buffered saline contain-
ing 0.1% Tween 20 and 10% defatted milk. Membranes
were then incubated with primary antibodies as de-
scribed in the figure legends for two hours at room
temperature. Secondary antibody conjugated with HRP
was used for a second incubation for one hour at room
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using chemiluminescent HRP substrate. Images were col-
lected using a chemical luminescence imaging system.
cAMP measurement
To measure intracellular cAMP, cells were seeded on
60-mm tissue culture plates at a density of 1 × 106 cells
per well. After 24 hours, cells were switched to a serum-
starved, phenol red-free (D)MEM medium for 5 hours
and then treated with E2, G1 or Tam as described in the
figure legends. After treatment, cells were washed with
PBS twice and frozen and thawed three times. The final
concentrations of cAMP were quantified using an
Enzyme Immunoassay Kit (R&D System, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Data were analyzed by measuring OD 590 values.
Cell apoptosis analyses
For these experiments, cells were seeded on 6-well plates
at a density of 1 × 105 cells per well. Two days later, cells
were treated with ethanol, Tam, G15, or G15 plus Tam
for 48 hours. At the end of the treatment, cells were
washed with PBS twice and collected by centrifuging at
2,000 rpm for five minutes. Cells were prepared by se-
quential addition of 500 μl binding buffer, 5 ml annexin
V-FITC and 5 μl propidium iodide following the manu-
facturer’s instructions (Keygenbio, Nanjing, China). Data
were analyzed using a BD FACSCalibur.
Breast cancer xenograft models
TAM-R xenograft models were established in female
ovariectomized athymic four- to six-week old nude mice
(Animal Experimental Center of Chongqing Medical
University, Chongqing, China) by implanting 5 × 106 cells
into mammary fat pads. Experiments were conducted in
accordance with guidelines on animal care and use estab-
lished by the Chongqing Medical University Experimental
Animal Management Committee. The Ethics Committee
of Chongqing Medical University approval was obtained
for the study. When tumors grew to 150 to 200 mm3 (five
to six weeks), the animals were randomly assigned to
experimental groups at n = 5 per group. Tam and G15
were dissolved in absolute ethanol and diluted to the
proper concentration with ethanol. For treatment with
these compounds, 10 μL was added to 90 μL aqueous
vehicle (0.9% NaCl with 0.1% albumin and 0.1% Tween-
20). The control group received 10 μL ethanol alone
added to 90 μL aqueous vehicle. Mice were given a
subcutaneous injection (0.1 ml/mouse) of ethanol, Tam
(50 μg), G15 (4 μg) or G15 (4 μg) plus Tam (50 μg) once
daily. Tumor volumes were measured with a vernier
caliper and calculated as 1/2 × length × width2 for tumors
derived from TAM-R cell implants (Additional file 1:
Table S1). At the end of the 56-day treatment, tumorswere removed and embedded in paraffin. To assay the
inhibitory effects of the treatment, sections were stu-
died using an In Situ Cell Death Detection Kit (Zsbio,
Beijing, China) following the manufacturer’s instruc-
tion. Samples were analyzed under a fluorescence
microscope.
Statistical analysis
The results are expressed as the means of three determi-
nations ± SD. Curve fittings were performed with the
Prism program (Graph Pad Software, San Diego, CA,
USA). Statistical analysis was carried out using Student’s
t test for paired observations. When three or more
means were compared, analysis of variance was applied
using the Prism program. Results were considered statis-
tically significant if P<0.05.
Results
Expression of GPR30 and EGFR in breast cancer tissues
According to the inclusion criteria, breast cancer tissue
specimens from 77 patients were eligible for analysis. Pa-
tients were considered GPR30+ if they had an IHC score
of at least 2. GPR30 was predominantly expressed on
plasma membranes and in cytoplasm, whereas EGFR
was localized to plasma membranes in tumor tissues
(Figure 1). GPR30 immunostaining patterns in breast
cancer tissue were negative (Figure 1a), slightly positive
(Figure 1b), moderately positive (Figure 1c), and strongly
positive (Figure 1d).
Sites of recurrence included 29 local and 48 distant
metastatic lesions; of these, 68.83% (53/77) of the
paraffin-embedded breast cancer specimens were classi-
fied as GPR30+. To determine the relationship between
GPR30 and tamoxifen resistance, GPR30 expression was
detected in PTs and their corresponding MTs. In 53 tu-
mors that recurred during treatment with tamoxifen,
GPR30 expression was increased in 73.58% (39/53),
decreased in 5.66% (3/53) and unchanged in 20.76%
(11/53) (Figure 1B). As shown in Figure 1C, the mean
IHC score for GPR30 was 3.46 ± 1.07 in PTs and 6.23 ±
0.91 in MTs, respectively (P<0.05). Also, in 77 MTs
assessed for EGFR, 61.03% (47/77) were EGFR + and
74.46% (35/47) showed EGFR overexpression; and in 53
MTs (GPR30+), GPR30 expression was positively corre-
lated with EGFR expression (R2 =0.8985, P<0.001).
Therapeutic concentration of tamoxifen alters MCF-7 cell
sensitivity to E2, G1 and Tam
Tam was tested on MCF-7 cells to assess variation in
their proliferative potential during endocrine therapy.
Acute exposure of MCF-7 cells to a therapeutic concen-
tration of Tam (1 × 10-6 M) caused massive cell death
over 5 days in medium supplemented with 5% FBS; how-
ever, the cytocidal effect of Tam was significantly
Figure 1 Paraffin-embedded breast cancer tissue immunostained with GPR30 or EGFR antibodies. The predominant staining pattern of
GPR30 was cytoplasmic in carcinoma tissue, whereas EGFR was mainly expressed on plasma membrane (A). Cytoplasmic GPR30 immunostaining
of breast tumors was (a) negative, (b) weak, (c) moderate or (d) strong. EGFR staining of breast tumors was (e) no staining, (f) moderate and
complete staining, or (g) strong and complete staining. GPR30 moderately stained primary tumors (h), but strongly stained corresponding tissue
during tamoxifen treatment (i). Quantitative (B) and paired (C) expression of GPR30 was compared in 53 matched tissues from primary tumors
(PTs) and their corresponding metastases (MTs). Pair-wise scatter plots showed the correlation of GPR30 and EGFR expression in MTs (D). EGFR,
epidermal growth factor receptor; GPR30, G-protein coupled receptor 30.
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continuous exposure to Tam. Exposure to 0.1% ethanol
over a 21-day period did not change the inhibitory ac-
tion of Tam (data not shown). Cells treated with Tam for21 days, showed strong resistance to the therapeutic
concentration of Tam and were termed TAM-R cells.
Growth effects of E2, G1 and Tam were investigated in
phenol-red free medium containing sufficient growth
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centration of E2 effectively promoted MCF-7 cell growth;
however, TAM-R cells showed more sensitivity to E2
growth stimulating effects. In contrast, a high concentra-
tion of the GPR30-specific agonist G1 stimulated only
slight growth in MCF-7 cells, but gave significantly en-
hanced proliferative effects on TAM-R cells (Figure 2A).
Although a low Tam concentration inhibited MCF-7 cell
growth, TAM-R cell growth could be stimulated despite
the presence of Tam (Figure 2B), showing that endocrine
treatment significantly altered the pattern of response to
Tam. Consistent with this observation above, the growth
response of TAM-R cells to E2 (1 × 10-10 M) was 30%
higher than MCF-7 cells, and this growth stimulation by
E2 could be suppressed completely by 1 × 10-6 M Tam in
MCF-7 cells, whereas it did not significantly inhibit the
proliferation of TAM-R cells.
Tam treatment not only shifted E2 and G1 dose–
response curves to the left, but also significantly altered
patterns of response to Tam, thus contributing to the
development of tamoxifen resistance in MCF-7 cells
(Figure 2).Growth stimulations of TAM-R cells in response to E2,
G1 and Tam were related to increased activation of
MAP kinases
Activation of EGFR downstream elements, such as
mitogen-activated protein kinases (MAPK) and phos-
phatidylinositol 3-kinase (PI-3 K), is an important mech-
anism of tamoxifen resistance. Also, the extra-cellularly
regulated protein kinases-1 and −2 (Erk1/2) are part of a
major MAPK pathway cascade, which mediates mitogen-
esis in hormone-sensitive breast cancer cells. To study
associations between EGFR activation and increased re-
sponses to E2, G1 and Tam after tamoxifen resistance de-
velopment, Erk1/2 phosphorylation levels were assayed.Figure 2 Effects of 17ß-estradiol (E2), GPR30 agonist G1, and Tam on
(TAM-R) cells. (A) Cells were counted five days after treatment with the in
after treatment with different concentrations of Tam. (C) Cells were treated
days. Each experiment was repeated at least three times; results are expres
G-protein coupled receptor; Tam, 4-hydroxytamoxifen.E2 treatment can induce Erk1/2 phosphorylation, but
patterns of phosphorylated-Erk1/2 (p-Erk1/2) differed
distinctly between MCF-7 and TAM-R cells. In TAM-R
cells, E2 induced p-Erk1/2 at 5 to 15 minutes, peaking at
10 minutes; in MCF-7 cells, Erk1/2 phosphorylation was
more gradual, at 5 to 15 minutes after E2-incubation
(Figure 3A).
TAM-R cells displayed higher Erk1/2 activation com-
pared to MCF-7 cells during G1 treatment (Figure 3B).
In TAM-R cells, earlier and significantly increased levels
of p-Erk1/2 were seen at 5 minutes, and decreased at
10 to 15 minutes. In contrast, G1-induced Erk1/2
phosphorylation in MCF-7 cells was much weaker at 5
to 10 minutes than in TAM-R cells.
Similarly, Tam treatment also mediated rapid phos-
phorylation of Erk1/2 in MCF-7 and TAM-R cells
(Figure 3C). In TAM-R cells, Tam can stimulate Erk1/
2 activation, with peak increases at 5 and 10 minutes.
Nevertheless, the activation of Erk1/2 induced by Tam
was much weaker which started to decrease from 5 to
15 minutes in MCF-7 cells.
All these results indicate that increased agonistic ef-
fects of E2, G1 and Tam, which stimulated TAM-R cell
proliferation, were related to inappropriate activation of
Erk1/2, which was an EGF downstream factor.
Increased Erk1/2activation was associated with intense
GPR30/EGFR crosstalk in TAM-R cells
Because activated GPR30 at the cell membrane pro-
motes HB-EGF release to activate the EGFR signaling
pathway, resulting in phosphorylation of Erk1/2 in breast
cancer cells, and TAM-R cells (as described above) in-
crease activation of Erk1/2 in response to E2, G1 and
Tam, the effect of GPR30 on EGFR signaling was tested
in TAM-R cells.
As shown in Figure 4, a strong phosphorylation of
EGFR was observed in TAM-R cells, while Tam inducedproliferation of parental MCF-7 cells and tamoxifen-resistant
dicated concentrations of E2 and G1. (B) Cells were counted five days
with 1 μM Tam in the presence of 10 nM E2 and counted after five
sed as means ± SD from three independent experiments. GPR30,
Figure 3 Activation of Erk1/2 responses to E2, G1 or Tam in MCF-7 and TAM-R cells. Erk1/2 expression was investigated by western blot
using specific antibodies against phosphorylated (p) and total (t) Erk1/2 protein. Cells were cultured for the indicated times with 1 nM E2 (A), 10
nM G1 (B) or 1 μM Tam (C) before preparation of cell lysates and western blot analysis. t-Erk1/2 expression was used as loading control. E2,
17β-estradiol; Tam, 4-hydroxytamoxifen; TAM-R, tamoxifen resistant.
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late Erk1/2 and EGFR phosphorylation. In TAM-R cells,
the GPR30-specific antagonist G15 could lower the
levels of phosphorylated EGFR and Erk1/2 in the pres-
ence of Tam, but not in the presence of EGF. However,Figure 4 Role of GPR30/EGFR signaling pathway in phosphorylation o
(control), 1 μM Tam or 10 ng/ml EGF alone or in combination with the GPR30
p-Erk1/2 and p-EGFR were detected by western blot using specific antibodies
(B). EGFR, epidermal growth factor receptor; GPR30, G-protein coupled receptTAM-R cells pre-incubated with the EGFR inhibitor
AG1478 could inhibit the ability of Tam or EGF to in-
crease the activation of EGFR and Erk1/2.
These data suggest that inappropriate activation of
Erk1/2 was related to the intense crosstalk of GPR30 tof Erk1/2 and EGFR in TAM-R cells. Cells were treated with ethanol
antagonist G15 or the EGFR inhibitor AG1478 for 10 minutes. Levels of
(A). Fold changes of expression were quantified, normalized to β-actin
or 30; Tam, 4-hydroxytamoxifen; TAM-R, tamoxifen resistant.
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oxifen resistance.
Translocation of GPR30 to cell surface facilitated GPR30/
EGFR crosstalk in TAM-R cells
Because phosphorylation of Erk1/2 in TAM-R cells ap-
parently depends on GPR30/EGFR crosstalk, we investi-
gated the mechanism of the GPR30–EGFR interaction.
As expected, green fluorescence was predominantly
assembled in membrane and cytoplasm, indicating cellu-
lar locations of GPR30 in both MCF-7 and TAM-R cells.
However, a variation was seen in TAM-R cells; whereas
membrane and cytoplasm in MCF-7 cells were mildlyFigure 5 Distribution and expression of GPR30 in MCF-7 and TAM-R c
immunofluorescent staining. (A) Cells were stained with DAPI, GPR30-GFP alo
MCF-7 and TAM-R cells were quantified by qPCR (B) and western blot (C). Fo
fractions of MCF-7 and TAM-R cells were normalized to β-actin (C). Each expe
means ± SD. *P <0.05 versus MCF-7 cells. DAPI, 4′, 6-diamidino-2-phenylindolestained, the degree of fluorescence was intensified in
TAM-R cells (Figure 5A). It seemed that GPR30 expres-
sion significantly increased in TAM-R cells.
To quantify the level of GPR30, total GPR30 expres-
sion was studied in MCF-7 and TAM-R cells. GPR30
mRNA levels relative to β-actin levels were quantified
using RT-PCR and comparative Δt methods. There was
no significant difference in mean GPR30 mRNA levels be-
tween MCF-7 and TAM-R cells (Figure 5B) nor in relative
expression of GPR30 protein normalized to β-actin in
MCF-7 cells and TAM-R cells, as shown by western blot
(Figure 5C). However, in enriched cytomembrane fractions
of MCF-7 and TAM-R, a difference in GPR30 proteinells. The GPR30 subcellular location was detected using
ne or a combination (Merge). GPR30 mRNA and protein expressions in
ld changes of GPR30 in total protein and membrane-enriched protein
riment was repeated at least three times. Results are expressed as
; GPR30, G-protein coupled receptor 30; TAM-R, tamoxifen resistant.
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relative level of GPR30 in the membrane fraction of
TAM-R was approximately 1.1 fold higher than in MCF-7
cells, indicating that a quantity of GPR30 had migrated to
the cell membrane in TAM-R cells.
All these results reveal that GPR30, through cytomem-
brane translocation, enhances its interaction with EGFR,
thus increasing Erk1/2 activation, leading to breast can-
cer proliferation during tamoxifen treatment.GPR30 attenuated inhibition of Erk1/2 activation by
reducing cAMP in TAM-R cells
Although membrane translocation of GPR30 can enhance
induction of EGFR downstream phosphorylation of Erk1/
2 in TAM-R cells, counter-intuitively, the GPR30 subunit
protein Gα can promote cAMP generation—which can at-
tenuate Erk1/2 activation—by inhibiting activity of protein
kinase A on RAF1. To elucidate the mechanism of GPR30
in stimulating Erk1/2 phosphorylation, intracellular cAMP
production was measured by ELISA.
In MCF-7 cells, basal cAMP concentration [cAMP]i was
identical to that in TAM-R cells (Figure 6). In MCF-7 cells,
E2 increased [cAMP]i to 10.46 ± 0.94 pmol, G1 to 12.32 ±
0.65 pmol, and Tam to 14.33 ± 0.88 pmol (Figure 6A). In
TAM-R cells, however, although rank orders of ligand-
mediated cAMP production were the same as in MCF-7
cells, magnitudes of the increases were much less: E2 in-
creased [cAMP]i in TAM-R cells to 8.59 ± 0.69 pmol, G1 to
9.96 ± 0.21 pmol, and Tam to 11.22 ± 0.66 pmol (Figure 6).
In TAM-R cells, GPR30 restricted its Gα subunit’s
ability to promote cAMP generation, thus attenuating
cAMP’s inhibition of Erk1/2 activation. GPR30 could,
therefore, balance inhibition and stimulation of EGFR
downstream elements that mediate Erk1/2 phosphoryl-
ation and promote tamoxifen resistance.Figure 6 Generation of cAMP mediated by GPR30 in MCF-7 and
TAM-R cells. Cells were incubated for five minutes with 1 nM E2,
10 nM G1 or 1 μM Tam; ELISA was then performed after preparation
of cell lysates. Each experiment was repeated at least three times.
Data show means ± SD. *P <0.05 versus similarly treated MCF-7
cells. E2, 17β-estradiol; GPR30, G-protein coupled receptor 30;
Tam, 4-hydroxytamoxifen; TAM-R, tamoxifen resistant.GPR30/EGFR crosstalk mediated TAM-R cell survival
As enhanced interaction between GPR30 and EGFR sig-
naling was seen to increase Erk1/2 phosphorylation in
TAM-R cells, and Erk1/2 activates gene transcription
leading to breast cancer proliferation, we investigated
the role of GPR30/EGFR crosstalk in cell survival.
Among MCF-7 cells, Tam-treated cells stayed in
early-phase apoptosis relative to ethanol-treated cells
(Figure 7A), which is consistent with a study showing
that tamoxifen and its active metabolites inhibit cell
survival by inducing early-phase apoptosis [2]. In con-
trast, the Tam-treated, G15-treated or G15/Tam-treated
groups did not significantly differ in the percentage of
cells in early-phase apoptosis (Figure 7A). However, G15/
Tam treatment induced some TAM-R cells to stay in early-
phase apoptosis, unlike Tam or G15 alone (Figure 7B). The
percentage of cells in early-phase apoptosis in each group
was quantified (Figure 7C). In MCF-7 cells, Tam treatment
led to 14.31 ± 0.35% increase in early-phase apoptosis com-
pared to ethanol-treated cells. Although Tam or G15 alone
did not significantly induce apoptosis in TAM-R cells,
when combined, they induced 10.63 ± 1.21% increase in
early-phase apoptosis.
These results indicate that GPR30 crosstalk with EGFR
signaling is crucial to the anti-cytocidal effect of tamoxi-
fen, which impels MCF-7 cells to develop tamoxifen
resistance.
GPR30 inhibitor G15 improved TAM-R xenograft response
to endocrine treatment
Because GPR30 influences TAM-R cell survival by inter-
acting with EGFR signaling under Tam exposure, effects
of combined therapy with the GPR30 specific antagonist
G15 and Tam on tamoxifen-resistant xenografts was
studied.
Tamoxifen-resistant tumors were visible by 35 to 42
days in female ovariectomized athymic nude mice. In
these experiments, the mean volume of ethanol-treated
tumors (control group) increased by 3.2-fold over 56
days, whereas the mean volumes of Tam-treated or G15-
treated tumors did not significantly differ from the
control group. However, combined treatment remark-
ably inhibited growth in tamoxifen-resistant xenografts
during the intervention (Figure 8A). At the end of treat-
ment, the combination group had approximately two-
fold reductions in tumor volume compared to controls
(Figure 8B). Moreover, this inhibition showed no obvious
toxicity, as body weight did not greatly change.
To investigate the anti-tumor effect of the target
treatment, growth inhibition was analyzed using paraf-
fin sections of TAM-R xenograft by TUNEL assay. In
TAM-R xenografts ethanol-treated (a), Tam-treated (b)
and G15-treated (c) cells showed slight staining by
TUNEL, but combination treatment (d) caused strong
Figure 7 Synergistic effects of GPR30 antagonist G15 and Tam on apoptosis. Cells were treated with ethanol (control), 1 μM Tam, 10 nM
G15 alone or 10 nM G15 plus 1 μM Tam for 48 hours using Annexin V-FITC flow cytometry. Scattergrams show numbers of MCF-7 (A) and TAM-R
(B) cells in early-phase apoptosis (EA) using the indicated treatments. (C) Histograms show percentages of MCF-7 (A) and TAM-R (B) cells in
early-phase apoptosis 48 hours after using the indicated treatments. Data show means ± SD from three independent experiments. * P<0.05,
versus control; ** P<0.05 versus Tam treatment. GPR30, G-protein coupled receptor 30; Tam, 4-hydroxytamoxifen; TAM-R, tamoxifen resistant.
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were quantified (Figure 8D). In control cells, ethanol
treatment caused 11.03 ± 1.01% apoptosis in TAM-R tu-
mors; this result is supported by those of Massarweh
et al., which indicated that low estrogen levels result in
a partial regression of hormone-dependent breast can-
cer due to induction of apoptosis [23]. The Tam- or
G15-treated groups also induced apoptosis in tumors of
8.17 ± 0.67% or 13.27 ± 1.31%, respectively. These ob-
servations correspond with previous tumor volume
studies. As expected, combination therapy with GPR30
antagonist G15 plus Tam had a massive anti-tumor ef-
fect on TAM-R xenografts, by approximately three-fold
over the control group.
These results imply that GPR30 is a stimulation factor
in tamoxifen-resistant xenograft growth, and inhibitingGPR30 activation by targeted therapy could restore the
curative effect of endocrine treatment to tamoxifen-
resistant breast cancer.
Discussion
In this study, we investigated the role of GPR30 in the
development of tamoxifen resistance in hormone-dependent
breast cancer. GPR30, a seven-transmembrane domain
G-protein coupled receptor [24], is expressed in approxi-
mately 50% of breast cancer patients and is thought to
induce rapid estrogen action in breast cancer cells [25,26].
Tamoxifen and its metabolites have been shown to stimu-
late breast cancer proliferation through GPR30 in these
particular circumstances [27-29]. Taken together, these
findings suggest that GPR30 promotes tamoxifen resistance
in patients with breast cancer during endocrine treatment.
Figure 8 Assessing the therapeutic effect of combination therapy with Tam plus G15 in a TAM-R xenograft. Nude mice bearing TAM-R
tumors were randomized on day 0 to receive ethanol alone, Tam (50 μg) alone, G15 (4 μg) alone or G15 (4 μg) in combination with Tam (50 μg)
(A). Images represent the xenograft tumors in monotherapy and combination therapy groups (B). Paraffin-embedded sections from ethanol alone
(a), Tam alone (b), G15 alone (c) or G15 in combination with Tam (d) were labeled for cellular apoptosis using Tunel (C). Histogram shows
percentage of apoptotic tumor cells induced by monotherapy or combination therapy for xenograft experiments (D). *P<0.05 versus ethanol
alone; ** P <0.05 versus Tam alone. Results are expressed as means ± SD. Tam, 4-hydroxytamoxifen; TAM-R, tamoxifen resistant.
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tients with ER+ breast cancer that over-expresses EGFR
and HER-2 have a lower sensitivity or shorter duration
of response to hormone therapy [30]. Inappropriate acti-
vation of growth factor receptors, especially in the EGFR
family, is reportedly responsible for development of tam-
oxifen resistance [5,31,32]. In breast cancer patients,
EGFR-targeted therapy suppresses tamoxifen-resistant
tumor progression [5]; however, the initial activator of
the EGFR signaling pathway is disputed. Reportedly,
approximately 50% of ER + breast cancer patients ex-
press GPR30, which coincides with the development oftamoxifen resistance [31,33]. In our study, expression of
GPR30 was significantly increased in MTs relative to
their corresponding PTs, and was also correlated with
EGFR expression in MTs. We, therefore, hypothesized
that further study of GPR30 would provide insight into
the development of tamoxifen resistance.
GPR30 is thought to be a new membrane-bound es-
trogen receptor, which differs from the classical nuclear
estrogen receptors α and β (ERα and ERβ) [34] and with
a disputed role as a functional estrogen receptor in
breast cancer cells. Many studies show that GPR30 col-
laborates with ER to transmit estrogen signaling; others
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cancer cells [27,35]. Our experiments found stimulation
in wild-type MCF-7 cells by E2 to be stronger than G1.
These results suggest that GPR30 plays a secondary role
in estrogen-induced proliferation in parent cells. In
TAM-R MCF-7 cells, the abilities of E2 and G1 to pro-
mote cell proliferation were significantly increased,
and Tam approaching a clinically relevant concentra-
tion (1 μM) stimulated cell growth. Thus, we can con-
clude that the capacity of GPR30 to mediate estrogen
action is significantly reinforced during development
of tamoxifen resistance in breast cancer cells.
Some of the very first reports indicated that the Gβγ
subunit protein of GPR30 greatly affects the GPR30/EGFR
signaling pathway [36]. Downstream of GPR30 signaling,
E2-induction leads to activation of the SRC-like tyrosine
kinase and metalloproteinases which, in turn, stimulates
extracellular release of HB-EGF, presumably through the
Gβγ subunit protein [37,38]. Release of HB-EGF allows it
to activate the EGFR signaling pathway, resulting in in-
duction of Erk1/2 phosphorylation with consequent
stimulation of cell growth [20]. As expected, E2, G1 or
Tam stimulates phosphorylation of Erk1/2 in MCF-7 cells.
Interestingly, a stronger and earlier phosphorylated Erk1/2
was observed in TAM-R cells during E2, G1 and Tam
treatment, respectively, although there was no significant
difference in basal levels of Erk1/2 between MCF-7 and
TAM-R cells. Moreover, these increased activations of
Erk1/2 were coincident with EGFR phosphorylation in
TAM-R cells. The GPR30-specific antagonist G15 could
significantly inhibit phosphorylation of Erk1/2 and EGFR
as did the EGFR inhibitor AG1478. We noted that GPR30
activation increased ligand-dependent EGFR activity, lead-
ing to an Erk1/2-mediated transcriptional response, thus
contributing to the development of tamoxifen resistance
in breast cancer cells.
As these observations indicate, GPR30 interaction with
the EGFR signaling pathway could be an important
mechanism in the development of tamoxifen resistance
in MCF-7 cells. In human breast cancer MTs, endocrine
treatment increases expression of GPR30 compared to
corresponding PTs. Further experiments showed that in-
creased GPR30 expression mainly occurred in mem-
branes of TAM-R cells, whereas the total GPR30
expression did not change. GPR30 seemed to enhance
interaction with the EGFR signaling pathway through its
translocation to the cell membrane.
Redistribution of ERα has been proposed as the mech-
anism of acquired tamoxifen resistance in breast cancer
[39], but, this hypothesis is disputed. ERα protein has no
hydrophobic transmembrane domains or membrane-
localizing sequences [40], and any potential role of
cytoplasmic ERα interaction in the EGFR pathway in de-
veloping tamoxifen resistance is unclear. ERα and EGFRexpression in human breast cancer tissue are also in-
versely correlated [41]; ERα seems to repress EGFR in
breast cancer cells [42].
On the other hand, the Gαs subunit of GPR30 has
been suggested to be responsible for E2 stimulation of
adenylate cyclase and the ensuing increase in cAMP
generation in breast cancer cells [21]. Production of
cAMP triggered by GPR30 can attenuate Erk1/2 activity
by suppressing protein kinase A (PKA) on RAF1 [37]. It
is likely that there is an exact balance between inhibition
and stimulation of the Erk1/2 pathway in MCF-7 cells
[43]. In our study, the basal cAMP level of MCF-7 cells
was similar to that of TAM-R cells, but E2-induced, G1-
induced or Tam-induced cAMP generation in TAM-R
cells was significantly lower than in MCF-7 cells. These
reductions of cAMP production which receded as a re-
sult of PKA inhibition led to increased activation of
Erk1/2 in TAM-R cells. All these results, showing that
GPR30 destroyed the exact balance mentioned above,
would promote the development of tamoxifen resistance
in MCF-7 cells during endocrine treatment, but the pre-
cise molecular mechanism to explain how GPR30 causes
an imbalance between inhibition and stimulation of the
Erk1/2 pathway induced by cAMP is unclear at the
present time. Further studies are needed to investigate
this process.
Several lines of evidence indicate that PP2, an inhibitor
of non-receptor tyrosine kinase c-Src—a mediator of the
EGFR signaling pathway—can abolish E2-induced Erk1/
2 phosphorylation and, thus, inhibit MCF-7 cell growth
[44]. In our study, GPR30 activation was inhibited by its
specific antagonist G15, thus restraining proliferation of
TAM-R cells by initiating apoptosis under Tam interven-
tion. These results are supported by the investigation of
Ignatov et al., which indicated that GPR30 anti-sense ol-
igonucleotides could eliminate GPR30 ligand-mediated
growth stimulation of TAM-R cells [45]. In the in vivo
study of the proliferative potential of GPR30, combin-
ation therapy of G15 plus Tam significantly reduced
TAM-R tumor size, whereas treatments with Tam or
G15 alone did not. GPR30-target treatment could
increase apoptosis in TAM-R xenografts, whereas apop-
tosis rates from Tam or G15 treatment do not signifi-
cantly differ from that of the ethanol-treated group.
Synergistic interaction of GPR30 and the EGFR sig-
naling pathway enhances breast cancer proliferation,
which allows tumor progression in the presence of
tamoxifen.
While several endocrine-resistant breast cancer models
are based on inappropriate activity of the EGFR signal-
ing pathway [8,22,23], the present model shows variable
activation of the EGFR downstream cascade [6]. Levels
of phosphorylated Erk1/2 increased transiently in our
TAM-R cells and in long-term tamoxifen-treated models
Figure 9 Role of GPR30 in the development of tamoxifen resistance. Long-term endocrine therapy can inhibit ERα-regulated gene transcription
in hormone-dependent breast cancer; whereas tamoxifen-facilitated translocation of GPR30 to the cell membrane enhances crosstalk with
EGFR signaling through the Gβγ subunit of GPR30. However, when treated with GPR30 plus tamoxifen, GPR30’s Gα subunit attenuates cAMP
suppression of Erk1/2 phosphorylation of an EGF downstream factor. As tamoxifen is an agonist for GPR30, endocrine therapy can stimulate
GPR30/EGFR crosstalk, leading to cell growth. When this activation effect exceeds ERα inhibition, breast cancer progresses under tamoxifen
treatment. Interrupting direct crosstalk between GPR30 and EGFR by use of a GPR30-specific antagonist (G15) induces both cytocidal action
in vitro and an antitumor effect in vivo. Targeted therapy with GPR30 could restore endocrine therapy response in tamoxifen-resistant breast
cancer. EGFR, epidermal growth factor receptor; ER, estrogen receptor; GPR30, G-protein coupled receptor 30.
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phosphorylation was observed in long-term estrogen-
deprived MCF-7 cells [48]. These differences may relate
to ways that breast cancer cells adapt to various endo-
crine treatments (drug therapy or estrogen deprivation)
[41,49,50]. Although inappropriate activation of the
EGFR signaling pathway is widely accepted as a key
mechanism of tamoxifen resistance, the initial factor that
transactivates EGFR is still disputed. Our study thus
aimed to demonstrate the role of GPR30 in the develop-
ment of tamoxifen resistance. In breast cancer MTs,
GPR30 expression significantly increased relative to cor-
responding PTs and correlated with EGFR expression.
Endocrine treatment caused increased ligand-dependent
activation of the EGFR downstream element Erk1/2,
with consequential growth stimulation—which would
lead breast cancer cells to develop tamoxifen resistance.
These phenomena were possibly related to translocation
of GPR30 to the cytomembrane and reduction of
GPR30-induced cAMP production. As crosstalk between
GPR30 and the EGFR signaling pathway intensified,
inhibited GPR30 activity could promote apoptosis initi-
ation in drug-resistant cells in the presence of tamoxifen.
Moreover, combination therapy with the GPR30 specific
antagonist G15 plus tamoxifen both restrained tumor
progression, and restored the cytocidal effect of tamoxi-
fen in drug-resistant xenografts. Our results provide ex-
perimental evidence of the important role of GPR30 in
the development of tamoxifen resistance, establishing anew therapeutic target to delay drug resistance or im-
prove response to endocrine treatment in cases that de-
velop tamoxifen resistance.
Conclusions
In summary, our findings suggest that long-term endo-
crine therapy facilitates translocation of GPR30 to cell
membranes, resulting in inappropriate activation of the
EGFR signaling pathway (Figure 9). Meanwhile, GPR30
attenuates the inhibitory effect of cAMP on MAP ki-
nases. Combination treatment with the GPR30 specific
antagonist G15 plus Tam induces both cytocidal action
in vitro and antitumor progression in vivo. Thus, GPR30
might be a useful target in developing better treatments
for TAM-R breast cancer patients.
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(d) groups. The data were recorded weekly until the 56th week.
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